Start Date
January 31, 2021
Primary Completion Date
January 31, 2021
Study Completion Date
January 31, 2021
Yaq-001
Study patients will be dosed daily with 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
Placebo
Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
Inselspital Universitaet Bern, Department for Visceral Surgery and Medicine, Bern
Hospital Ramon y Cajal, Department of Gastroenterology and Hepatology, Madrid
Azienda Ospedaliera di Padova, Hepatic Emergencies Unit, Padua
Policlinico S.Orsola Malpighi, Department of Medical and Surgical Sciences, Bologna
Hospital Beaujon, Hepatology and Liver Intensive Care,, Clichy
University Hospital of Santa Maria, Lisbon
Hospital Vall d'Hebron, Liver Unit, Barcelona
Hospital Clinic of Barcelona , Liver Unit,, Barcelona
Royal Free Hospital, Institute of Liver and Digestive Disease, London
Collaborators (1)
University College, London
OTHER
Servicio Madrileño de Salud, Madrid, Spain
OTHER
Hospital Universitari Vall d'Hebron Research Institute
OTHER
Azienda Ospedaliera di Padova
OTHER
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
University of Bern
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
University of Lisbon
OTHER
Alpha Bioresearch S.L.
OTHER
Institut d'Investigacions Biomèdiques August Pi i Sunyer
OTHER
University of Brighton
OTHER
A2F Associates Limited
OTHER
Yaqrit Ltd
INDUSTRY